Sökning: WFRF:(Simren Magnus) > How the Change in I...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04372naa a2200457 4500 | |
001 | oai:gup.ub.gu.se/270400 | |
003 | SwePub | |
008 | 240910s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2704002 URI |
024 | 7 | a https://doi.org/10.1038/s41395-018-0074-z2 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Aziz, Imranu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition4 aut0 (Swepub:gu)xaziim |
245 | 1 0 | a How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2018 |
520 | a OBJECTIVES: The diagnostic criteria for irritable bowel syndrome (IBS) have recently been updated from Rome III to Rome IV. Whereas in Rome III a diagnosis of IBS entailed chronic abdominal pain or discomfort at least 3 days per month, in Rome IV the term discomfort has been removed and the frequency of abdominal pain increased to at least 1 day per week. We examined how this change in IBS criteria impacts on clinical characteristics and pathophysiological factors. METHODS: A total of 542 Swedish subjects with Rome III IBS completed a baseline questionnaire enquiring for the number of abdominal pain days in the last 10 days; this was subsequently used as a surrogate marker to identify Rome IV IBS, in that (a) those with 0 or 1 day of pain were classed as Rome IV-negative, and (b) those with >= 2 days of pain were classed as Rome IV-positive. Comparisons were made between Rome IV-positive and -negative IBS groups for demographics, IBS subtype, gastrointestinal and psychological symptoms, somatisation, fatigue, disease-specific quality of life, rectal sensitivity, and oro-anal transit time. RESULTS: Overall, 85% of Rome III IBS patients fulfilled the Rome IV criteria for IBS, but 15% did not. Rome IV-positive subjects were significantly more likely to be female, have poorer quality of life, greater pain severity, bloating, somatisation, fatigue, and rectal sensitivity than Rome IV-negative subjects. There were no differences in severity of anxiety or depression, IBS subtypes, bowel habit dissatisfaction, or oro-anal transit time. Finally, increasing number of pain days correlated positively with symptoms and visceral hypersensitivity. CONCLUSIONS: Most Rome III-positive IBS patients seeking healthcare fulfil the Rome IV IBS criteria. They constitute a more severe group than those who lose their IBS diagnosis. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
653 | a irritable-bowel-syndrome | |
653 | a quality-of-life | |
653 | a cross-sectional survey | |
653 | a transit-time | |
653 | a symptoms | |
653 | a scale | |
653 | a questionnaire | |
653 | a metaanalysis | |
653 | a prevalence | |
653 | a severity | |
653 | a Gastroenterology & Hepatology | |
700 | 1 | a Törnblom, Hans,d 1966u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition4 aut0 (Swepub:gu)xtornh |
700 | 1 | a Palsson, O. S.4 aut |
700 | 1 | a Whitehead, W. E.4 aut |
700 | 1 | a Simrén, Magnus,d 1966u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition4 aut0 (Swepub:gu)xsimrm |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition4 org |
773 | 0 | t American Journal of Gastroenterologyd : Ovid Technologies (Wolters Kluwer Health)g 113:7, s. 1017-1025q 113:7<1017-1025x 0002-9270 |
856 | 4 | u https://cdr.lib.unc.edu/downloads/6t053n51g |
856 | 4 8 | u https://gup.ub.gu.se/publication/270400 |
856 | 4 8 | u https://doi.org/10.1038/s41395-018-0074-z |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy